June 23/30, 2015

Medical MarijuanaIs the Cart Before the Horse?

Author Affiliations
  • 1Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut
  • 2Psychiatry Service, VA Connecticut Healthcare System, West Haven
  • 3Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven

Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2015;313(24):2431-2432. doi:10.1001/jama.2015.6407

There is a pressing need to develop new medications for many debilitating conditions. Novel approaches based on marijuana or its constituent cannabinoids, if proven, could be added to the armamentarium of available treatments. In this issue of JAMA, reviews by Whiting et al1 and Hill2 provide detailed assessment of the pharmacology, indications, benefits, adverse effects, and laws related to medical marijuana and the cannabinoids, and the results and conclusions are consistent. There is some evidence to support the use of marijuana for nausea and vomiting related to chemotherapy, specific pain syndromes, and spasticity from multiple sclerosis. However, for most other indications that qualify by state law for use of medical marijuana, such as hepatitis C, Crohn disease, Parkinson disease, or Tourette syndrome, the evidence supporting its use is of poor quality. State laws vary widely regarding conditions for which marijuana is approved and the dispensable legal limit. Both reviews raise important issues worthy of further discussion.

First Page Preview View Large
First page PDF preview
First page PDF preview